Eurobio Scientific SA
PAR:ALERS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.8
25.95
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Eurobio Scientific SA
Eurobio Scientific SA
Total Liabilities
Eurobio Scientific SA
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Liabilities
€141.3m
|
CAGR 3-Years
45%
|
CAGR 5-Years
29%
|
CAGR 10-Years
20%
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities
€300.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
Total Liabilities
€95.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
12%
|
CAGR 10-Years
36%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities
€97.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
17%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities
€118.5m
|
CAGR 3-Years
60%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Total Liabilities
€59.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Eurobio Scientific SA
Glance View
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
See Also
What is Eurobio Scientific SA's Total Liabilities?
Total Liabilities
141.3m
EUR
Based on the financial report for Jun 30, 2024, Eurobio Scientific SA's Total Liabilities amounts to 141.3m EUR.
What is Eurobio Scientific SA's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
20%
Over the last year, the Total Liabilities growth was 2%. The average annual Total Liabilities growth rates for Eurobio Scientific SA have been 45% over the past three years , 29% over the past five years , and 20% over the past ten years .
You don't have any saved screeners yet
